Abstract Number: 1767 • 2016 ACR/ARHP Annual Meeting
Poor Body Image in Lupus: Is It Disease Activity, Damage, Sleep, Pain, Fatigue, Stress, Function, Medications, Depression or Fibromyalgia?
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have poorer body image (BI) than age matched controls. Few studies have been done looking at the effect…Abstract Number: 1768 • 2016 ACR/ARHP Annual Meeting
Fatigue in SLE Is Associated with Neuropsychiatric Involvement, Pain, Impaired Sleep and a Reduced Quality of Life
Background/Purpose: Fatigue is a major patient complaint in SLE, often severely impacting quality of life and activities including work. In this study, we analyze neuropsychiatric…Abstract Number: 1769 • 2016 ACR/ARHP Annual Meeting
Fatigue in Anti-Nuclear Antibody Positive Individuals with Insufficient Criteria to Diagnose a Systemic Autoimmune Rheumatic Disease
Background/Purpose: Fatigue is a common symptom of Systemic Autoimmune Rheumatic Disease (SARD) and has been proposed to result from the elaboration of pro-inflammatory factors in…Abstract Number: 1770 • 2016 ACR/ARHP Annual Meeting
The Impact of Comorbidities on Quality of Life in Systemic Lupus Erythematosus in the First 10 Years
The Impact of Comorbidities on Quality of Life in Systemic Lupus Erythematosus in the first 10 years Background/Purpose: The Medical Outcome Survey Short Form…Abstract Number: 1771 • 2016 ACR/ARHP Annual Meeting
Depression Is Associated with a Poorer with Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease with frequent involvement of the central nervous system. Among the items included in the nomenclature…Abstract Number: 1773 • 2016 ACR/ARHP Annual Meeting
Risk Factors for Cerebrovascular Events in Systemic Lupus Erythematosus: Results from an International, Inception Cohort Study
Background/Purpose: Neuropsychiatric (NP) disease in patients with SLE includes cerebrovascular events (CerVE). We determined the frequency, attribution and risk factors for CerVE in a large,…Abstract Number: 1774 • 2016 ACR/ARHP Annual Meeting
Chronological Analysis of Damage Accrual in Patientes with Systemic Lupus Erythematosus: Results from the Spanish Registry of Patients with SLE of the Spanish Society of Rheumatology (RELESSER)
Background/Purpose: Mortality in systemic lupus erythematosus (SLE) has improved over the last decades. Outcome measures as damage became more important. Objectives: To study the manifestations…Abstract Number: 1775 • 2016 ACR/ARHP Annual Meeting
Smoking As a Predictor of Cutaneous Activity in Systemic Lupus Erythematosus
ACR Abstract Authors: Shawn G. Kwatra1, Wei Fu2, Michelle Petri2 1Department of Dermatology, 2Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD Title:…Abstract Number: 1776 • 2016 ACR/ARHP Annual Meeting
Analysis of Progressive Brain and Corpus Callosum Atrophy and Association with Th1 and Th2 Cytokines in Systemic Lupus Erythematosus
Background/Purpose: The pathophysiology of brain damage SLE is complex. The aim of this study was to determine brain atrophy progression and the association with Th1…Abstract Number: 1777 • 2016 ACR/ARHP Annual Meeting
The Accumulation of Organ Damage, Public Insurance Enrollment and Youth Are Associated with Increased Hospitalizations in a Population-Based Cohort of Lupus Patient
Background/Purpose: Individuals with systemic lupus erythematosus (SLE) are frequently hospitalized. Determining factors associated with hospitalization rates may help to identify patients at highest risk for…Abstract Number: 1778 • 2016 ACR/ARHP Annual Meeting
Differences Between Early and Late Cardiovascular Disease in a Population-Based Cohort of Systemic Lupus Erythematosus Patients
Background/Purpose: It has long been known that mortality after years of systemic lupus erythematosus (SLE) is often associated with cardiovascular disease (CVD). Recent studies have…Abstract Number: 1779 • 2016 ACR/ARHP Annual Meeting
Remission and Low Lupus Disease Activity Status (LLDAS) Protect Lupus Patients from Damage Occurrence: Data from a Multi-Ethnic, Multinational Latin American Lupus Cohort
Background/Purpose: Recently, definitions of both Remission and LLDAS have been proposed which include disease activity status and medication intake [immunosuppressive (IS) drugs and corticosteroids]. The…Abstract Number: 1780 • 2016 ACR/ARHP Annual Meeting
Pulmonary Disease in Late Versus Early Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Background/Purpose: Phenotypes often differ in late-onset systemic lupus erythematosus (SLE) compared to SLE features in early-onset patients. Prior studies have suggested that there may be…Abstract Number: 1781 • 2016 ACR/ARHP Annual Meeting
Analysis of Influences of Various Factors on the Prognosis of Acute Confusional State of Diffuse Psychiatric/Neuropsychological Syndromes in Systemic Lupus Erythematosus
Background/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE), especially diffuse psychiatric/neuropsychological syndromes (diffuse NPSLE), is one of the most difficult complications of the disease. For the evaluation…Abstract Number: 1782 • 2016 ACR/ARHP Annual Meeting
Subclinical Myocarditis in Systemic Lupus Erythematosus Patients without Cardiovascular Disease
Background/Purpose : Cardiovascular disease (CVD) remains a leading cause of death in SLE. Lupus patients have a 2-3 fold increased risk to develop heart failure…
